The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future
- 9 April 2004
- journal article
- review article
- Published by Elsevier in Leukemia Research
- Vol. 28 (9) , 891-900
- https://doi.org/10.1016/j.leukres.2004.01.011
Abstract
No abstract availableKeywords
This publication has 109 references indexed in Scilit:
- JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cellsBlood, 2004
- Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA groupBlood, 2003
- Arsenic Trioxide Inhibits Neuroblastoma Growth in Vivo and Promotes Apoptotic Cell Death in VitroBiochemical and Biophysical Research Communications, 2000
- Arsenic — New Life for an Old PotionNew England Journal of Medicine, 1998
- Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic TrioxideNew England Journal of Medicine, 1998
- Function and Activation of NF-kappaB in the Immune SystemAnnual Review of Immunology, 1994
- Glutathione plays different roles in the induction of the cytotoxic effects of inorganic and organic arsenic compounds in cultured BALB/c 3T3 cellsCellular and Molecular Life Sciences, 1994
- The IκB proteins: members of a multifunctional familyTrends in Genetics, 1993
- Arsenic-Induced Atypical Ventricular TachycardiaNew England Journal of Medicine, 1980
- Action of Iron, Cod-liver Oil, and Arsenic on the Globular Richness of the BloodThe Lancet Healthy Longevity, 1878